Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Jan;61(1):101–109. doi: 10.1038/bjc.1990.22

Direct search methods in the optimisation of cancer chemotherapy regimens.

M C Berenbaum 1
PMCID: PMC1971319  PMID: 2297481

Abstract

Current cancer chemotherapy regimens may involve 20-30 or more independent variables, each affecting therapeutic response and toxicity. With standard response surface modelling methods, finding the optimum combination with as few as 10 variables entails testing over 1,000 combinations, so these methods do not provide a feasible approach to such problems. However, they may be tackled by direct search methods (DSM), i.e. stepwise searches of the response surface. Experiments were carried out in advanced L1210 leukaemia treated with combinations of adriamycin with cyclophosphamide, isophosphamide with acetylcysteine and methotrexate with leucovorin. Two established DSM (Nelder-Mead and Box) were used, and a new method was designed to find consistent search paths in spite of wide biological variation. With methotrexate and leucovorin, DSM located combinations prolonging mean survival to 40-50 days (compared with 10.4 in controls) and giving high proportions of long-term survivors. These results were achieved with single injections of drugs given 7 days after injection of 10(6) leukaemic cells, i.e. 2-3 days before deaths began in untreated mice, and appear to be unprecedented with these agents. Searching for optimal combinations of established agents may be at least as rewarding as searching for new agents, and thus DSM may prove a powerful tool for improving the results of combination cancer chemotherapy.

Full text

PDF
101

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Avery T. L., Roberts D. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia. Cancer Res. 1977 Mar;37(3):678–683. [PubMed] [Google Scholar]
  2. Carter W. H., Jr, Jones D. E., Carchman R. A. Application of response surface methods for evaluating the interactions of soman, atropine, and pralidioxime chloride. Fundam Appl Toxicol. 1985 Dec;5(6 Pt 2):S232–S241. doi: 10.1016/0272-0590(85)90133-2. [DOI] [PubMed] [Google Scholar]
  3. Carter W. H., Jr, Wampler G. L., Crews S. L., Howells R. On determining the levels of treatment to optimize the probability of a favorable response. Cancer Treat Rep. 1977 Aug;61(5):849–853. [PubMed] [Google Scholar]
  4. Carter W. H., Jr, Wampler G. L., Stablein D. M., Campbell E. D. Drug activity and therapeutic synergism in cancer treatment. Cancer Res. 1982 Aug;42(8):2963–2971. [PubMed] [Google Scholar]
  5. GOLDIN A., VENDITTI J. M., HUMPHREYS S. R., MANTEL N. Quantitative evaluation of chemotherapeutic agents against advanced leukemia in mice. J Natl Cancer Inst. 1958 Sep;21(3):495–511. [PubMed] [Google Scholar]
  6. Kline I., Gang M., Woodman R. J., Cysyk R. L., Venditti J. M. Protection with N-acetyl-L-cysteine (NSC-111180) against isophosphamide (NSC-109724) toxicity and enhancement of therapeutic effect in early murine L1210 leukemia. Cancer Chemother Rep. 1973 Sep-Oct;57(3):299–304. [PubMed] [Google Scholar]
  7. Nixon P. F., Wilson L. Identical efficacy of methotrexate regimens with N5-methyltetrahydrofolate rescue or with leucovorin rescue for treatment of L1210 murine leukemia. Cancer Treat Rep. 1983 Jan;67(1):59–62. [PubMed] [Google Scholar]
  8. SKIPPER H. E., SCHABEL F. M., Jr, WILCOX W. S. EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA. Cancer Chemother Rep. 1964 Feb;35:1–111. [PubMed] [Google Scholar]
  9. Sirotnak F. M., Moccio D. M., Dorick D. M. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Cancer Res. 1978 Feb;38(2):345–353. [PubMed] [Google Scholar]
  10. Solana R. P., Chinchilli V. M., Wilson J., Carter W. H., Jr, Carchman R. A. Estimation and analysis of the concentration-response surfaces associated with multiple-agent combinations. Toxicol Appl Pharmacol. 1986 Sep 15;85(2):231–238. doi: 10.1016/0041-008x(86)90117-1. [DOI] [PubMed] [Google Scholar]
  11. Stablein D. M., Carter W. H., Jr, Wampler G. L. Survival analysis of drug combinations using a hazards model with time-dependent covariates. Biometrics. 1980 Sep;36(3):537–546. [PubMed] [Google Scholar]
  12. Tobias J. S., Parker L. M., Tattersall M. H., Frei E., 3rd Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia. Br J Cancer. 1975 Aug;32(2):199–207. doi: 10.1038/bjc.1975.150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Wampler G. L., Carter W. H., Jr, Williams V. R. Combination chemotherapy: arriving at optimal treatment levels by incorporating side effect constraints. Cancer Treat Rep. 1978 Mar;62(3):333–340. [PubMed] [Google Scholar]
  14. Wilson J. D., Carter W. H., Jr, Campbell E. D., Kessler F. K., Carchman R. A. Application of response-surface methodology to detect interactions of genotoxic agents in cultured mammalian cells. J Toxicol Environ Health. 1986;19(2):173–183. doi: 10.1080/15287398609530918. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES